JP2019508458A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508458A5
JP2019508458A5 JP2018548424A JP2018548424A JP2019508458A5 JP 2019508458 A5 JP2019508458 A5 JP 2019508458A5 JP 2018548424 A JP2018548424 A JP 2018548424A JP 2018548424 A JP2018548424 A JP 2018548424A JP 2019508458 A5 JP2019508458 A5 JP 2019508458A5
Authority
JP
Japan
Prior art keywords
immunoglobulin
serum
less
igm
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018548424A
Other languages
English (en)
Japanese (ja)
Other versions
JP7041634B2 (ja
JP2019508458A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/055838 external-priority patent/WO2017157850A1/en
Publication of JP2019508458A publication Critical patent/JP2019508458A/ja
Publication of JP2019508458A5 publication Critical patent/JP2019508458A5/ja
Application granted granted Critical
Publication of JP7041634B2 publication Critical patent/JP7041634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018548424A 2016-03-14 2017-03-13 重症市中肺炎の処置 Active JP7041634B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16160175.2 2016-03-14
EP16160175 2016-03-14
EP16185173.8 2016-08-22
EP16185173 2016-08-22
PCT/EP2017/055838 WO2017157850A1 (en) 2016-03-14 2017-03-13 Treatment of severe community acquired pneumonia

Publications (3)

Publication Number Publication Date
JP2019508458A JP2019508458A (ja) 2019-03-28
JP2019508458A5 true JP2019508458A5 (https=) 2020-04-23
JP7041634B2 JP7041634B2 (ja) 2022-03-24

Family

ID=58413057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548424A Active JP7041634B2 (ja) 2016-03-14 2017-03-13 重症市中肺炎の処置

Country Status (10)

Country Link
US (4) US20190076523A1 (https=)
EP (2) EP3851123A1 (https=)
JP (1) JP7041634B2 (https=)
CN (1) CN108778333A (https=)
AU (1) AU2017233923B2 (https=)
CA (1) CA3013849A1 (https=)
ES (1) ES2881201T3 (https=)
PL (1) PL3429622T3 (https=)
RU (1) RU2735680C2 (https=)
WO (1) WO2017157850A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CA3195385A1 (en) 2020-11-19 2022-05-27 Biotest Ag Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
CN112485448B (zh) * 2020-11-20 2021-08-24 浙江大学 Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001319A1 (en) 1977-08-18 1979-04-04 Beecham Group Plc Process for the preparation of hydroxyphenyl hydantoin and of hydroxyphenyl glycine, and compounds thus obtained
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
EP2101787B1 (en) * 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US20130196310A1 (en) 2008-05-20 2013-08-01 Rapid Pathogen Screening, Inc. Method and Device for Combined Detection of Viral and Bacterial Infections
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
RU2470664C2 (ru) * 2010-08-23 2012-12-27 Андрей Германович Лютов Способ получения иммуноглобулина для внутривенного введения, обогащенного иммуноглобулином м, и препарат, полученный этим способом
ES2751976T3 (es) 2012-03-09 2020-04-02 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor

Similar Documents

Publication Publication Date Title
JP2025172841A5 (https=)
JP6441888B2 (ja) 自己免疫性障害の処置におけるレボセチリジン及びモンテルカストの使用
US10471142B2 (en) Combination therapy using immunoglobulin and C1-Inhibitor
EP2442832B1 (en) Compositions and methods for treatment of multiple sclerosis
BR112015006189A2 (pt) anticorpo anti-gm-csf, composição farmacêutica, e, uso de um anticorpo anti-gm-csf na fabricação de um medicamento
Sengsayadeth et al. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
RU2016149316A (ru) Лечение ревматоидного артрита
JP2019508458A5 (https=)
RU2018135290A (ru) Лечение тяжелой внебольничной пневмонии
AU2021247258A1 (en) Anti-CD6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including COVID-19
RU2473364C2 (ru) Способ лечения клещевого энцефалита
Uttamani et al. Therapeutic Modalities in the management of COVID-19: A worldwide landscape
RU2281784C1 (ru) Способ предупреждения клещевого энцефалита у детей
JP7621411B2 (ja) 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品
KR20210021356A (ko) 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체
Cleppe et al. Single High-Dose Oral Vitamin D3 (Stoss Dose) in Lieu of Daily Dosing is Reliably Effective for Treatment of Vitamin D Insufficiency/Deficiency in Pediatric Hematopoetic Stem Cell Transplant (HSCT) Recipients
Aghamohammadi et al. Adverse effects of intravenous immunoglobulin therapy in patients with antibody deficiency
Pang et al. A case of malathion poisoning with prolonged cholinergic toxicity
Wuysang The Role of Intravenous Immunoglobulin (IVIG) in Guillain-Barré Syndrome Treatment
CA2848510C (en) Combination therapy using immunoglobulin and c1-inhibitor
JP2025126668A (ja) 人免疫グロブリンgを有効成分として含有する、腎臓移植後の抗体関連型拒絶反応の治療剤
UA145596U (uk) Спосіб профілактики вірусних захворювань респіраторної групи
JP2002542205A (ja) 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置
Braun-Moscovici Leflunomide/rituximab
Tab et al. PSEUDOMEMBRANOUS COLITIS